• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚焦于不寻常的 ECL2 相互作用,得到具有前所未有的支架的β-肾上腺素受体拮抗剂。

A Focus on Unusual ECL2 Interactions Yields β -Adrenergic Receptor Antagonists with Unprecedented Scaffolds.

机构信息

Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marbacher Weg 6, 35037, Marburg, Germany.

InterAx Biotech, PARK innovAARE, 5234, Villigen, Switzerland.

出版信息

ChemMedChem. 2020 May 19;15(10):882-890. doi: 10.1002/cmdc.201900715. Epub 2020 Apr 17.

DOI:10.1002/cmdc.201900715
PMID:32301583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7318225/
Abstract

The binding pockets of aminergic G protein-coupled receptors are often targeted by drugs and virtual screening campaigns. In order to find ligands with unprecedented scaffolds for one of the best-investigated receptors of this subfamily, the β -adrenergic receptor, we conducted a docking-based screen insisting that molecules would address previously untargeted residues in extracellular loop 2. We here report the discovery of ligands with a previously undescribed coumaran-based scaffold. Furthermore, we provide an analysis of the added value that X-ray structures in different conformations deliver for such docking screens.

摘要

胺能 G 蛋白偶联受体的结合口袋通常是药物和虚拟筛选活动的目标。为了为该亚家族研究最充分的受体之一β-肾上腺素受体找到具有前所未有的支架的配体,我们进行了基于对接的筛选,坚持认为分子将针对细胞外环 2 中以前未靶向的残基。我们在这里报告了具有以前未描述的香豆素骨架的配体的发现。此外,我们还分析了不同构象的 X 射线结构为这种对接筛选带来的附加价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/4032ffafafe1/CMDC-15-882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/b43e2cf96109/CMDC-15-882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/cd0ab467bff3/CMDC-15-882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/bb01f51d5572/CMDC-15-882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/4032ffafafe1/CMDC-15-882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/b43e2cf96109/CMDC-15-882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/cd0ab467bff3/CMDC-15-882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/bb01f51d5572/CMDC-15-882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9b/7318225/4032ffafafe1/CMDC-15-882-g004.jpg

相似文献

1
A Focus on Unusual ECL2 Interactions Yields β -Adrenergic Receptor Antagonists with Unprecedented Scaffolds.聚焦于不寻常的 ECL2 相互作用,得到具有前所未有的支架的β-肾上腺素受体拮抗剂。
ChemMedChem. 2020 May 19;15(10):882-890. doi: 10.1002/cmdc.201900715. Epub 2020 Apr 17.
2
Ligand-binding affinity of alternative conformers of human β -adrenergic receptor in the presence of intracellular loop 3 (ICL3) and their potential use in virtual screening studies.人β-肾上腺素受体在细胞内环 3(ICL3)存在下的不同构象的配体结合亲和力及其在虚拟筛选研究中的潜在应用。
Chem Biol Drug Des. 2019 May;93(5):883-899. doi: 10.1111/cbdd.13478. Epub 2019 Feb 12.
3
Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.基于结构的 G 蛋白偶联受体配体功能预测:β-肾上腺素能受体案例研究。
J Chem Inf Model. 2015 May 26;55(5):1045-61. doi: 10.1021/acs.jcim.5b00066. Epub 2015 May 1.
4
Discovery of high affinity ligands for β2-adrenergic receptor through pharmacophore-based high-throughput virtual screening and docking.通过基于药效团的高通量虚拟筛选和对接发现β2-肾上腺素能受体的高亲和力配体。
J Mol Graph Model. 2014 Sep;53:148-160. doi: 10.1016/j.jmgm.2014.07.007. Epub 2014 Jul 21.
5
Bitopic Ligands Support the Presence of a Metastable Binding Site at the β Adrenergic Receptor.双位配体支持β肾上腺素受体中存在亚稳定结合位点。
J Med Chem. 2024 Jul 11;67(13):11053-11068. doi: 10.1021/acs.jmedchem.4c00578. Epub 2024 Jul 1.
6
Structure-based discovery of beta2-adrenergic receptor ligands.基于结构的β2-肾上腺素能受体配体的发现
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6843-8. doi: 10.1073/pnas.0812657106. Epub 2009 Apr 2.
7
The Principles of Ligand Specificity on beta-2-adrenergic receptor.β-2 肾上腺素能受体配体特异性的原理。
Sci Rep. 2016 Oct 5;6:34736. doi: 10.1038/srep34736.
8
Mechanism of intracellular allosteric βAR antagonist revealed by X-ray crystal structure.X射线晶体结构揭示细胞内变构β肾上腺素能受体拮抗剂的作用机制
Nature. 2017 Aug 24;548(7668):480-484. doi: 10.1038/nature23652. Epub 2017 Aug 16.
9
Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β-adrenergic receptor.设计、合成和功能评估 Cmpd-15 衍生物作为β-肾上腺素能受体的负变构调节剂。
Bioorg Med Chem. 2018 May 15;26(9):2320-2330. doi: 10.1016/j.bmc.2018.03.023. Epub 2018 Mar 15.
10
Ligand entry and exit pathways in the beta2-adrenergic receptor.β2肾上腺素能受体中的配体进出途径。
J Mol Biol. 2009 Oct 2;392(4):1102-15. doi: 10.1016/j.jmb.2009.07.093. Epub 2009 Aug 6.

引用本文的文献

1
Photo-clenbuterol: Optical Control of β-Adrenergic Receptor Signaling by Photoswitchable Ligand Efficacy.光控克伦特罗:通过可光开关配体效能对β-肾上腺素能受体信号进行光学控制
J Med Chem. 2025 Jun 26;68(12):12911-12924. doi: 10.1021/acs.jmedchem.5c00792. Epub 2025 Jun 10.
2
Synthesis and Pharmacological Characterization of New Photocaged Agonists for Histamine H and H Receptors.组胺H1和H2受体新型光笼激动剂的合成与药理学特性研究
Pharmaceuticals (Basel). 2024 Apr 21;17(4):536. doi: 10.3390/ph17040536.

本文引用的文献

1
How Significant Are Unusual Protein-Ligand Interactions? Insights from Database Mining.不常见的蛋白质-配体相互作用有多重要?数据库挖掘的见解。
J Med Chem. 2019 Nov 27;62(22):10441-10455. doi: 10.1021/acs.jmedchem.9b01545. Epub 2019 Nov 15.
2
Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy.比较对接独特的 G 蛋白偶联受体构象只能产生具有激动剂效能的配体。
Mol Pharmacol. 2019 Dec;96(6):851-861. doi: 10.1124/mol.119.117515. Epub 2019 Oct 17.
3
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report.
普萘洛尔治疗婴幼儿肝血管瘤的疗效:病例报告
Medicine (Baltimore). 2019 Jan;98(4):e14078. doi: 10.1097/MD.0000000000014078.
4
Structural insights into binding specificity, efficacy and bias of a βAR partial agonist.βAR 部分激动剂结合特异性、效力和偏向性的结构见解。
Nat Chem Biol. 2018 Nov;14(11):1059-1066. doi: 10.1038/s41589-018-0145-x. Epub 2018 Oct 16.
5
Three Generations of β-blockers: History, Class Differences and Clinical Applicability.三代β受体阻滞剂:历史、类别差异与临床适用性
Curr Hypertens Rev. 2019;15(1):22-31. doi: 10.2174/1573402114666180918102735.
6
Nanobody-Enabled Reverse Pharmacology on G-Protein-Coupled Receptors.纳米抗体介导的 G 蛋白偶联受体反向药理学研究。
Angew Chem Int Ed Engl. 2018 May 4;57(19):5292-5295. doi: 10.1002/anie.201712581. Epub 2018 Mar 30.
7
Trends in GPCR drug discovery: new agents, targets and indications.G蛋白偶联受体(GPCR)药物研发趋势:新药物、靶点与适应症
Nat Rev Drug Discov. 2017 Dec;16(12):829-842. doi: 10.1038/nrd.2017.178. Epub 2017 Oct 27.
8
Function-specific virtual screening for GPCR ligands using a combined scoring method.使用组合评分方法对GPCR配体进行功能特异性虚拟筛选。
Sci Rep. 2016 Jun 24;6:28288. doi: 10.1038/srep28288.
9
ZINC 15--Ligand Discovery for Everyone.锌15——面向大众的配体发现平台。
J Chem Inf Model. 2015 Nov 23;55(11):2324-37. doi: 10.1021/acs.jcim.5b00559. Epub 2015 Nov 9.
10
A cAMP Biosensor-Based High-Throughput Screening Assay for Identification of Gs-Coupled GPCR Ligands and Phosphodiesterase Inhibitors.一种基于环磷酸腺苷生物传感器的高通量筛选分析方法,用于鉴定与Gs偶联的G蛋白偶联受体配体和磷酸二酯酶抑制剂。
J Biomol Screen. 2015 Aug;20(7):849-57. doi: 10.1177/1087057115580019. Epub 2015 Apr 7.